Robert Jr. Spignesi Sells 17,922 Shares of Rapid Micro Biosystems (NASDAQ:RPID) Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CEO Robert Jr. Spignesi sold 17,922 shares of the company’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $4.11, for a total value of $73,659.42. Following the sale, the chief executive officer owned 1,169,848 shares in the company, valued at approximately $4,808,075.28. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Rapid Micro Biosystems Price Performance

Shares of Rapid Micro Biosystems stock traded down $0.96 on Thursday, reaching $3.42. The stock had a trading volume of 514,590 shares, compared to its average volume of 133,521. The business’s 50 day moving average is $3.97 and its two-hundred day moving average is $3.54. The company has a current ratio of 4.23, a quick ratio of 2.95 and a debt-to-equity ratio of 0.42. Rapid Micro Biosystems, Inc. has a 1 year low of $1.86 and a 1 year high of $4.94. The company has a market cap of $151.58 million, a P/E ratio of -3.39 and a beta of 1.38.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%. The firm had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. As a group, research analysts anticipate that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current year.

Hedge Funds Weigh In On Rapid Micro Biosystems

A number of institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Rapid Micro Biosystems by 1.6% during the 2nd quarter. Geode Capital Management LLC now owns 204,079 shares of the company’s stock valued at $704,000 after buying an additional 3,143 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after acquiring an additional 5,341 shares during the last quarter. Renaissance Technologies LLC grew its position in Rapid Micro Biosystems by 4.9% in the fourth quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after acquiring an additional 5,440 shares in the last quarter. Susquehanna International Group LLP increased its stake in Rapid Micro Biosystems by 12.6% in the third quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock valued at $195,000 after acquiring an additional 6,528 shares during the last quarter. Finally, Hudson Bay Capital Management LP bought a new position in Rapid Micro Biosystems in the third quarter valued at $38,000. Institutional investors own 52.60% of the company’s stock.

Rapid Micro Biosystems News Roundup

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: New multi-system order from Samsung Biologics reinforces commercial traction for the Growth Direct automation platform and expands deployment across a large CDMO customer network — a clear revenue-growth catalyst. Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics
• Positive Sentiment: Company reported record Q4 and full‑year 2025 revenue (Q4 revenue $11.3M, FY2025 $33.6M), and Q4 revenue beat the Street — evidence demand and placements are growing. Rapid Micro Biosystems Reports Record Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Earnings call transcript and summaries provide color on growth initiatives and customer pipeline but did not materially change the near‑term outlook; read for management commentary on placements, margin drivers and execution risks. Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed expectations (reported ($0.28) vs. consensus ($0.23)), and profitability remains weak (large negative net margin and negative ROE) — these metrics keep the stock in a riskier profile and may slow multiple expansion. RPID Earnings / Conference Call
• Negative Sentiment: The company issued FY2026 revenue guidance of $37.0M–$41.0M (management expects ~30–38 system placements) — the midpoint is slightly below consensus (~$39.7M), which, combined with high operating losses, likely weighed on sentiment. 2026 Guidance in Press Release
• Negative Sentiment: Recent insider selling by CEO, CFO and COO (multiple Form 4 filings show sales in March) can amplify downward pressure on the stock even if sales are for diversification or liquidity. SEC Form 4 — Spignesi sale

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on RPID shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. Wall Street Zen upgraded Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Rapid Micro Biosystems has a consensus rating of “Hold” and an average price target of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.